Cargando…

Increased Reflux Esophagitis after Helicobacter pylori Eradication Therapy in Cases Undergoing Endoscopic Submucosal Dissection for Early Gastric Cancer

SIMPLE SUMMARY: Helicobacter pylori infection is associated with the development of gastric cancer. Reflux esophagitis may occur in the postoperative period of patients undergoing surgical therapy for gastric cancer. The role of eradication therapy of Helicobacter pylori in reflux esophagitis is con...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsurahara, Masaki, Imoto, Ichiro, Umeda, Yuhei, Miura, Hiroshi, Tsuboi, Junya, Yamada, Reiko, Yasuma, Taro, Nakamura, Misaki, Hamada, Yasuhiko, Inoue, Hiroyuki, Tanaka, Kyosuke, Horiki, Noriyuki, Gabazza, Esteban C., Takei, Yoshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068244/
https://www.ncbi.nlm.nih.gov/pubmed/33917861
http://dx.doi.org/10.3390/cancers13081779
_version_ 1783682990680834048
author Katsurahara, Masaki
Imoto, Ichiro
Umeda, Yuhei
Miura, Hiroshi
Tsuboi, Junya
Yamada, Reiko
Yasuma, Taro
Nakamura, Misaki
Hamada, Yasuhiko
Inoue, Hiroyuki
Tanaka, Kyosuke
Horiki, Noriyuki
Gabazza, Esteban C.
Takei, Yoshiyuki
author_facet Katsurahara, Masaki
Imoto, Ichiro
Umeda, Yuhei
Miura, Hiroshi
Tsuboi, Junya
Yamada, Reiko
Yasuma, Taro
Nakamura, Misaki
Hamada, Yasuhiko
Inoue, Hiroyuki
Tanaka, Kyosuke
Horiki, Noriyuki
Gabazza, Esteban C.
Takei, Yoshiyuki
author_sort Katsurahara, Masaki
collection PubMed
description SIMPLE SUMMARY: Helicobacter pylori infection is associated with the development of gastric cancer. Reflux esophagitis may occur in the postoperative period of patients undergoing surgical therapy for gastric cancer. The role of eradication therapy of Helicobacter pylori in reflux esophagitis is controversial. Here, we evaluated the occurrence of reflux esophagitis before and after Helicobacter pylori eradication in patients having endoscopic submucosal resection for early gastric cancer. Reflux esophagitis before and after eradication therapy was evaluated during the follow-up. While reflux esophagitis incidence increased from 3.1% to 18.8% in the successful eradication group, no case of reflux esophagitis was observed in the failed eradication group. There was a significant correlation between successful Helicobacter pylori eradication rate and reflux esophagitis development. This study demonstrates that a successful Helicobacter pylori eradication therapy is a risk factor for newly developed reflux esophagitis in patients having endoscopic submucosal dissection for early gastric cancer. ABSTRACT: Background: The role of Helicobacter pylori in the pathogenesis of reflux esophagitis is controversial. This study investigated the frequency of reflux esophagitis before and after H. pylori eradication in patients having endoscopic submucosal dissection for early gastric cancer. Methods: This study included 160 patients that fulfilled the study’s criteria. Endoscopy was performed before and after H. pylori eradication, and reflux esophagitis was evaluated during the follow-up period. Results: Seropositivity for H. pylori in patients with early gastric cancer was 68.8%, 101 of them received eradication therapy. During the follow-up period, the incidence of reflux esophagitis increased from 3.1% to 18.8% in the successful eradication group but no case of reflux esophagitis was observed in the failed eradication group. The univariate and multivariate analyses showed a significant correlation between successful H. pylori eradication rate and the development of reflux esophagitis. Conclusions: This study demonstrated that a successful H. pylori eradication therapy is a risk factor for newly developed reflux esophagitis in patients with endoscopic submucosal dissection for early gastric cancer.
format Online
Article
Text
id pubmed-8068244
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80682442021-04-25 Increased Reflux Esophagitis after Helicobacter pylori Eradication Therapy in Cases Undergoing Endoscopic Submucosal Dissection for Early Gastric Cancer Katsurahara, Masaki Imoto, Ichiro Umeda, Yuhei Miura, Hiroshi Tsuboi, Junya Yamada, Reiko Yasuma, Taro Nakamura, Misaki Hamada, Yasuhiko Inoue, Hiroyuki Tanaka, Kyosuke Horiki, Noriyuki Gabazza, Esteban C. Takei, Yoshiyuki Cancers (Basel) Brief Report SIMPLE SUMMARY: Helicobacter pylori infection is associated with the development of gastric cancer. Reflux esophagitis may occur in the postoperative period of patients undergoing surgical therapy for gastric cancer. The role of eradication therapy of Helicobacter pylori in reflux esophagitis is controversial. Here, we evaluated the occurrence of reflux esophagitis before and after Helicobacter pylori eradication in patients having endoscopic submucosal resection for early gastric cancer. Reflux esophagitis before and after eradication therapy was evaluated during the follow-up. While reflux esophagitis incidence increased from 3.1% to 18.8% in the successful eradication group, no case of reflux esophagitis was observed in the failed eradication group. There was a significant correlation between successful Helicobacter pylori eradication rate and reflux esophagitis development. This study demonstrates that a successful Helicobacter pylori eradication therapy is a risk factor for newly developed reflux esophagitis in patients having endoscopic submucosal dissection for early gastric cancer. ABSTRACT: Background: The role of Helicobacter pylori in the pathogenesis of reflux esophagitis is controversial. This study investigated the frequency of reflux esophagitis before and after H. pylori eradication in patients having endoscopic submucosal dissection for early gastric cancer. Methods: This study included 160 patients that fulfilled the study’s criteria. Endoscopy was performed before and after H. pylori eradication, and reflux esophagitis was evaluated during the follow-up period. Results: Seropositivity for H. pylori in patients with early gastric cancer was 68.8%, 101 of them received eradication therapy. During the follow-up period, the incidence of reflux esophagitis increased from 3.1% to 18.8% in the successful eradication group but no case of reflux esophagitis was observed in the failed eradication group. The univariate and multivariate analyses showed a significant correlation between successful H. pylori eradication rate and the development of reflux esophagitis. Conclusions: This study demonstrated that a successful H. pylori eradication therapy is a risk factor for newly developed reflux esophagitis in patients with endoscopic submucosal dissection for early gastric cancer. MDPI 2021-04-08 /pmc/articles/PMC8068244/ /pubmed/33917861 http://dx.doi.org/10.3390/cancers13081779 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Katsurahara, Masaki
Imoto, Ichiro
Umeda, Yuhei
Miura, Hiroshi
Tsuboi, Junya
Yamada, Reiko
Yasuma, Taro
Nakamura, Misaki
Hamada, Yasuhiko
Inoue, Hiroyuki
Tanaka, Kyosuke
Horiki, Noriyuki
Gabazza, Esteban C.
Takei, Yoshiyuki
Increased Reflux Esophagitis after Helicobacter pylori Eradication Therapy in Cases Undergoing Endoscopic Submucosal Dissection for Early Gastric Cancer
title Increased Reflux Esophagitis after Helicobacter pylori Eradication Therapy in Cases Undergoing Endoscopic Submucosal Dissection for Early Gastric Cancer
title_full Increased Reflux Esophagitis after Helicobacter pylori Eradication Therapy in Cases Undergoing Endoscopic Submucosal Dissection for Early Gastric Cancer
title_fullStr Increased Reflux Esophagitis after Helicobacter pylori Eradication Therapy in Cases Undergoing Endoscopic Submucosal Dissection for Early Gastric Cancer
title_full_unstemmed Increased Reflux Esophagitis after Helicobacter pylori Eradication Therapy in Cases Undergoing Endoscopic Submucosal Dissection for Early Gastric Cancer
title_short Increased Reflux Esophagitis after Helicobacter pylori Eradication Therapy in Cases Undergoing Endoscopic Submucosal Dissection for Early Gastric Cancer
title_sort increased reflux esophagitis after helicobacter pylori eradication therapy in cases undergoing endoscopic submucosal dissection for early gastric cancer
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068244/
https://www.ncbi.nlm.nih.gov/pubmed/33917861
http://dx.doi.org/10.3390/cancers13081779
work_keys_str_mv AT katsuraharamasaki increasedrefluxesophagitisafterhelicobacterpylorieradicationtherapyincasesundergoingendoscopicsubmucosaldissectionforearlygastriccancer
AT imotoichiro increasedrefluxesophagitisafterhelicobacterpylorieradicationtherapyincasesundergoingendoscopicsubmucosaldissectionforearlygastriccancer
AT umedayuhei increasedrefluxesophagitisafterhelicobacterpylorieradicationtherapyincasesundergoingendoscopicsubmucosaldissectionforearlygastriccancer
AT miurahiroshi increasedrefluxesophagitisafterhelicobacterpylorieradicationtherapyincasesundergoingendoscopicsubmucosaldissectionforearlygastriccancer
AT tsuboijunya increasedrefluxesophagitisafterhelicobacterpylorieradicationtherapyincasesundergoingendoscopicsubmucosaldissectionforearlygastriccancer
AT yamadareiko increasedrefluxesophagitisafterhelicobacterpylorieradicationtherapyincasesundergoingendoscopicsubmucosaldissectionforearlygastriccancer
AT yasumataro increasedrefluxesophagitisafterhelicobacterpylorieradicationtherapyincasesundergoingendoscopicsubmucosaldissectionforearlygastriccancer
AT nakamuramisaki increasedrefluxesophagitisafterhelicobacterpylorieradicationtherapyincasesundergoingendoscopicsubmucosaldissectionforearlygastriccancer
AT hamadayasuhiko increasedrefluxesophagitisafterhelicobacterpylorieradicationtherapyincasesundergoingendoscopicsubmucosaldissectionforearlygastriccancer
AT inouehiroyuki increasedrefluxesophagitisafterhelicobacterpylorieradicationtherapyincasesundergoingendoscopicsubmucosaldissectionforearlygastriccancer
AT tanakakyosuke increasedrefluxesophagitisafterhelicobacterpylorieradicationtherapyincasesundergoingendoscopicsubmucosaldissectionforearlygastriccancer
AT horikinoriyuki increasedrefluxesophagitisafterhelicobacterpylorieradicationtherapyincasesundergoingendoscopicsubmucosaldissectionforearlygastriccancer
AT gabazzaestebanc increasedrefluxesophagitisafterhelicobacterpylorieradicationtherapyincasesundergoingendoscopicsubmucosaldissectionforearlygastriccancer
AT takeiyoshiyuki increasedrefluxesophagitisafterhelicobacterpylorieradicationtherapyincasesundergoingendoscopicsubmucosaldissectionforearlygastriccancer